The effect of combined expression of interleukin 2 and interleukin 4 on the tumorigenicity and treatment of B16F10 melanoma

British Journal of Cancer

Volumn 74, Issue 1, 1996, Pages 6-15

  Hollingsworth, S J ^a   Darling, D ^a   Gaken J ^a   Hirst, W ^a   Patel, P ^a   Kuiper, M ^a   Towner, P ^a   Humphreys, S ^a   Farzaneh, F ^a   Mufti, G J ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Gene therapy; Interleukin 2; Interleukin 4; Murine melanoma

Indexed keywords

CANCER VACCINE; DNA; INTERLEUKIN 2; INTERLEUKIN 4;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER INHIBITION; CARCINOGENICITY; CELL INFILTRATION; CONTROLLED STUDY; DNA METHYLATION; GENETIC TRANSDUCTION; GRANULOCYTE; HISTOPATHOLOGY; INFLAMMATION; LYMPHOCYTE; MACROPHAGE; MELANOMA B16; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 8944241297     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.308     Document Type: Article

References (34)

1. AOKI T, TASHIRO K, MIYATAKE S-I, KINASHI T, NAKANO T, ODA Y, KIKUCHI H, AND HONJO T. (1992). Expression of murine interleukin 7 in a murine glioma cell line results in reduced tumorigenicity in vivo. Proc. Natl Acad. Sci. USA, 89, 3850-3854.
2. BASKAR S, OSTRAND-ROSENBERG S, NABAVI N, NADLER LM, FREEMAN GJ AND GLIMCHER LH. (1993). Constitutive expression of B7 restores immunogenicity of tumour cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl Acad. Sci. USA, 90, 5687-5690.
3. BLANKENSTEIN T, QIN Z, UBERLA K, MULLER W, ROSEN H, VOLK H-D AND DIAMANTSTEIN T. (1991). Tumor suppression after tumor cell-targeted tumor necrosis factor α gene transfer. J. Exp. Med., 173, 1047-1052.
4. COLOMBO M, FERRARI G, STOPPACCIARO A, PARENZA M, RODOLFO M, MAVILIO F AND PARMIANI G. (1991). Granulocyte colony-stimulating factor gene transfer supresses tumorigenicity of a murine adenocarcinoma in vivo. J. Exp. Med., 173, 889-897.
5. COLOMBO MP AND FORNI G. (1994). Cytokine gene transfer in tumor inhibition and tumor therapy: Where are we now? Immunol. Today, 15, 48-51.
6. DRANOFF G, JAFFRE E, LAZENBY A, GOLUMBEK P, LEVITSKY H, BROSE K, JACKSON V, HAMADA H, PARDOLL D AND MULLIGAN RC. (1993). Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA, 90, 3538-3543.
7. FEARON E, ITAYA T, HUNT B, VOGELSTEIN B AND FROST P. (1988). Induction in a murine tumor of immunogenic tumor variants by transfection with a foreign gene. Cancer Res., 48, 2975-2980.
8. FEARON E, PARDOLL D, ITAYA T, GOLUMBEK P, LEVITSKY HI, SIMONS JW, KARASUYAMA H, VOGELSTEIN B AND FROST P. (1990). Interleukin-2 production by tumour cells bypasses T helper function in the generation of an anti-tumour response. Cell, 60, 397-403.
9. FIDLER IJ. (1975). Biological behaviour of malignant melanoma cells correlated to their survival in vivo. Cancer Res., 35, 218-234.
10. GÄKEN J, STOCKING C, OSTERTAG W AND FARZANEH F. (1992). Construction of a versatile set of retroviral vectors conferring hygromycin resistance. BioTechniques, 13, 32-34.
11. GANSBACHER B, ZIER K, DANIELS B, CRONIN K, BANNERJI R AND GILBOA E. (1990a). Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med., 172, 1217-1224.
12. GANSBACHER B, BANNERJI R, DANIELS B, ZIER K, CRONIN K AND GILBOA E. (1990b). Retroviral vector-mediated γ-interferon gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res., 50, 7820-7825.
13. GOLUMBEK PT, LAZENBY AJ, LEVITSKY HI, JAFFEE LM, KARASUYAMA H, BAKER M AND PARDOLL DM. (1991). Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science, 254, 713-717.
14. HEWITT HB, BLAKE ER AND WALDER AS. (1976). A critique of the evidence for active host defence against cancer, based on personal studies of 27 murine tumours of spontaneous origin. Br. J. Cancer, 33, 241-259.
15. KLEIN G, SJOGREN H, KLEIN E AND HELLSTROM K. (1960). Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res., 20, 1561-1572.
16. LEY V, LANGLADE-DEMOYEN P, KOURILSKY P AND LARSSONSCIARD E. (1991). Interleukin 2-dependent activation of tumour-specific cytotoxic T lymphocytes in vivo. Eur. J. Immunol., 21, 851-854.
17. LI W, DIAMANTSTEIN T AND BLANKENSTEIN T. (1990). Lack of tumorigenicity of interleukin 4 autocrine growing cells seems related to the anti-tumor function of interleukin 4. Mol. Immunol., 27, 1331-1337.
18. LI Y, MCGOWAN P, HELLSTRÖM I, HELLSTRÖM KE AND CHEN L. (1994). Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma. J. Immunol, 153, 421-435.
19. MARKOWITZ D, GOFF S AND BANK A. (1988). Construction and use of a safe and efficient amphotropic packaging cell line. Virology, 167, 400-406.
20. MILLER A AND BUTTIMORE C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol., 6, 2895-2902.
21. MORGENSTERN J AND LAND H. (1990). Advanced mammalian gene transfer; high titre retroviral vectors with multiple drug selection markers and a complementary helper-free packaging cell line. Nucleic Acids Res., 18, 3581-3596.
22. OETTGEN HF AND OLD LJ. (1991). In: Biological Therapy of Cancer, DeVita VT, Hellman S and Rosenberg, SA, (eds) pp. 87-119. Lippincott: Philadelphia.
23. PATEL PM, FLEMMING CL, RUSSELL SJ, MCKAY IA, MACLENNAN KA, BOX GM, ECCLES SA AND COLLINS MKL. (1993). Comparison of the potential therapeutic effects of interleukin 2 or interleukin 4 secretion by a single tumour. Br. J. Cancer, 68, 295-302.
24. PORGADOR A, TZEHOVAL E, KATZ A, VADAI E, REVEL M, FELDMAN M AND EISENBACH L. (1992). Interleukin 6 gene transfection into Lewis lung carcinoma tumor cells suppresses the malignant phenotype and confers immunotherapeutic competence against parental metastatic cells. Cancer Res., 52, 3679-3686.
25. PORGADOR A, BANNERJI R, WATANABE Y, FELDMAN M, GILBOA E AND EISENBACH L. (1993). Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted tumor cells. J. Immunol., 150, 1458-1470.
26. RUSSELL S, ECCLES S, FLEMMING C, JOHNSON C AND COLLINS M. (1991). Decreased tumorigenicity of a transplantable rat sarcoma following transfer and expression of an IL-2 cDNA. Int. J. Cancer, 47, 244-251.
27. SALVADORI S, GANSBACHER B, PIZZIMENTI AM AND ZIER KS. (1994). Abnormal signal transduction by T cells of mice with parental tumours is not seen in mice bearing IL-2-secreting tumours. J. Immunol., 153, 5176-5182.
28. SUGIURA C, ITAYA T, KONDOH N, OIKAWA T, KUZUMAKI N, TAKEICHI N, HOSOKAWA M AND KOBAYASHI H. (1988). Xenogenization of tumor cells by transfection with plasmid containing env gene of Friend leukaemia virus. Jpn. J. Cancer Res., 79, 1259-1263.
29. TENG MN, PARK BH, KOEPPEN HK, FENDLY BM AND SCHREIBER H. (1991). Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc. Natl Acad. Sci. USA, 88, 3535-3539.
30. TEPPER R, PATTENGALE, P AND LEDER P. (1989). Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell, 57, 503-512.
31. TEPPER R, COFFMAN R AND LEDER P. (1992). An eosinophil-dependent mechanism for the anti-tumor effect of interleukin-4. Science, 257, 548-551.
32. VERDEGAAL EME, BEEKHUIZEN H, BLOKLAND I AND VANFURTH R. (1993). Increased adhesion of human monocytes to IL-4-stimulated human venous endothelial cells via CD11/CD18, and very late antigen-4 (VLA-4)/vascular cell adhesion molecule-1 (VCAM-1)-dependent mechanisms. Clin. Exp. Immunol., 93, 292-298.
33. WALLICH R, BULBUC N, HAMMERLING G, KATZAV S, SEGAL S AND FELDMAN M. (1985). Abrogation of metastatic properties of tumor cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature, 315, 301-305.
34. WATANABE Y, KURIBAYASHI K, MIYATAKE S, NISHIHARA K, NAKAYAMA E-I, TANIYAMA T AND SAKATA T-A. (1989). Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented anti-tumour immunity. Proc. Natl Acad. Sci. USA, 86, 9456-9460.